Rashidian Maryam, Bastan Fatemeh, Soltani Hedieh, Ghosheni Reza, Bakhshande Kiyarash, Mohammaditabar Mahdi, Mehr Yasin Tabatabaei, Rahmani Khaled, Bakhtiyari Mahmood, Qorbani Mostafa, Forootan Mojgan, Mohammadi Mahsa, Rajabnia Mohsen
Student Research Committee, School of Medicine, Alborz University of Medical Sciences, Karaj, Iran.
Alborz Office of USERN, Universal Scientific Education and Research Network (USERN), Alborz University of Medical Sciences, Karaj, Iran.
BMC Gastroenterol. 2025 Apr 2;25(1):217. doi: 10.1186/s12876-025-03822-1.
Barrett's esophagus (BE) is a premalignant columnar metaplasia of the esophagus that predisposes victims to esophageal adenocarcinoma (EAC). Depending on differences in the study population and risk factors, the prevalence of BE may vary, from 0.4 to 20% globally. The current study aimed to systematically review and analyse the prevalence of BE in in patients with gastrointestinal symptoms in Iran. Furthermore, gastrointestinal malignancies are among the most common tumours in Iran, making this study even more significant.
A systematic search was carried out in PubMed, Web of Science, Scopus, and EMBASE as well as some domestic databases including SID, Magiran, IranDoc, IranMedex from inception to the end of 2023. We included all cross-sectional studies which reported the prevalence of BE and calculated pooled prevalence.
The results of the analysis, including 9 studies in a total of 4978 cases (213 Barret diagnoses), revealed that by the results of these studies, the prevalence of Barret's esophagus is 4.4% [I2 = 94.9% [92.2%; 96.6%]/p-value < 0.0001]. Subgroup analysis, divided by region and year, revealed significant differences between groups.
The epidemiology of BE in Iran is not completely identified. This is the first systematic review and meta-analysis evaluating the prevalence and of BE in Iran. Due to the importance of BE in progressing to esophageal adenocarcinoma, much importance should be given to its timely diagnosis. It is strongly recommended to conduct more comprehensive studies including more patients in this field.
巴雷特食管（BE）是一种食管的癌前柱状上皮化生，使患者易患食管腺癌（EAC）。根据研究人群和危险因素的不同，BE的患病率可能有所差异，全球范围为0.4%至20%。本研究旨在系统评价和分析伊朗有胃肠道症状患者中BE的患病率。此外，胃肠道恶性肿瘤是伊朗最常见的肿瘤之一，这使得本研究更具意义。
从创刊至2023年底，在PubMed、科学网、Scopus和EMBASE以及一些国内数据库（包括SID、Magiran、IranDoc、IranMedex）中进行了系统检索。我们纳入了所有报告BE患病率并计算合并患病率的横断面研究。
分析结果包括9项研究，共4978例病例（213例巴雷特诊断），结果显示，根据这些研究结果，巴雷特食管的患病率为4.4%[I2 = 94.9%[92.2%；96.6%]/p值<0.0001]。按地区和年份进行的亚组分析显示各亚组间存在显著差异。
伊朗BE的流行病学情况尚未完全明确。这是首次对伊朗BE的患病率进行系统评价和荟萃分析。鉴于BE在进展为食管腺癌方面的重要性，应高度重视其早期诊断。强烈建议在该领域开展更全面的研究，纳入更多患者。
